United Therapeutics (UTHR)
(Delayed Data from NSDQ)
$304.81 USD
+12.16 (4.16%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $304.88 +0.07 (0.02%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth F Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
UTHR 304.81 +12.16(4.16%)
Will UTHR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for UTHR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for UTHR
UTHR Q2 Earnings Miss Estimates, Higher Tyvaso Sales Aid Revenues Y/Y
Here's Why United Therapeutics (UTHR) is a Strong Growth Stock
UTHR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Compared to Estimates, United Therapeutics (UTHR) Q2 Earnings: A Look at Key Metrics
United Therapeutics (UTHR) Misses Q2 Earnings Estimates
Earnings Preview: Ardelyx (ARDX) Q2 Earnings Expected to Decline
Other News for UTHR
United Therapeutics (UTHR) Launches $1 Billion Share Buyback
United Therapeutics (UTHR) Launches $1B Stock Buyback Program
United Therapeutics enters $1B accelerated share repurchase program
United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program | ...
United Therapeutics announces $1B accelerated share repurchase program